Taisuke Kuroda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Taisuke Kuroda has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Mita
Clinical Veterinary Medicine Division Equine Research Institute, Japan Racing Association Shimotsuke Japan
13 shared publications- Yohei Minamijima
Drug Analysis Department Laboratory of Racing Chemistry Utsunomiya Japan
13 shared publications - Motoi Nomura
Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association, Tochigi, 329-0412, Japan
11 shared publications Minoru Ohta
9 shared publicationsNorihisa Tamura
Equine Research Institute, Japan Racing Association, Tochigi, Japan
9 shared publicationsKentaro Fukuda
Clinical Veterinary Medicine Division, Equine Research Institute, Japan Racing Association
8 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (11) , 1456-1469
Population Pharmacokinetics and Detection Times of Betamethasone After Intravenous, Intramuscular, and Intranasal Jet Administration of Betamethasone Sodium Phosphate in Horses
Betamethasone sodium phosphate (BETP) is a glucocorticosteroid used in humans. The primary objective was to estimate irrelevant plasma (IPC) and urine (IUC) concentrations using a pharmacokinetic/pharmacodynamic approach based on systemic clearance estimated from intravenous (IV) pharmacokinetic data. As a secondary objective, detection times (DTs) following IV, intramuscular (IM), and intranasal jet (INJ) administration were estimated for medication control. Plasma and urine concentrations were obtained from a total of 20 horses in Japan and Germany, with some horses contributing to more than one route after single IV (0.06 mg/kg, n = 7; 0.04 mg/kg, n = 8), single IM (20 mg/horse, n = 7), and multiple INJ (4 mg/horse for 5 days, n = 6) administration. The data were analyzed using a nonlinear mixed‐effects model. The plasma clearance was 276 mL/kg/h, and the steady‐state urine‐to‐plasma ratio was 25.8. For IV administration at 0.06 and 0.04 mg/kg every 24 h, the IPCs were 0.018 and 0.012 ng/mL, and the corresponding IUCs were 0.47 and 0.31 ng/mL, with the latter IUC close to the current International Federation of Horseracing Authorities international screening limit (ISL) (0.2 ng/mL). All horses fell below the ISL within 72 h after single IV administration at 0.06 and 0.04 mg/kg and after single IM administration, whereas all horses fell below the ISL within 48 h after INJ administration. The applicability of the estimated DTs should be interpreted according to the regulatory framework governing the use of human BETP formulations and their routes of administration in the relevant jurisdiction.
- 3 September 2026
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (11) , 1456-1469
Open AccessPopulation Pharmacokinetics and Detection Times of Betamethasone After Intravenous, Intramuscular, and Intranasal Jet Administration of Betamethasone Sodium Phosphate in Horses
Betamethasone sodium phosphate (BETP) is a glucocorticosteroid used in humans. The primary objective was to estimate irrelevant plasma (IPC) and urine (IUC) concentrations using a pharmacokinetic/pharmacodynamic approach based on systemic clearance estimated from intravenous (IV) pharmacokinetic data. As a secondary objective, detection times (DTs) following IV, intramuscular (IM), and intranasal jet (INJ) administration were estimated for medication control. Plasma and urine concentrations were obtained from a total of 20 horses in Japan and Germany, with some horses contributing to more than one route after single IV (0.06 mg/kg, n = 7; 0.04 mg/kg, n = 8), single IM (20 mg/horse, n = 7), and multiple INJ (4 mg/horse for 5 days, n = 6) administration. The data were analyzed using a nonlinear mixed‐effects model. The plasma clearance was 276 mL/kg/h, and the steady‐state urine‐to‐plasma ratio was 25.8. For IV administration at 0.06 and 0.04 mg/kg every 24 h, the IPCs were 0.018 and 0.012 ng/mL, and the corresponding IUCs were 0.47 and 0.31 ng/mL, with the latter IUC close to the current International Federation of Horseracing Authorities international screening limit (ISL) (0.2 ng/mL). All horses fell below the ISL within 72 h after single IV administration at 0.06 and 0.04 mg/kg and after single IM administration, whereas all horses fell below the ISL within 48 h after INJ administration. The applicability of the estimated DTs should be interpreted according to the regulatory framework governing the use of human BETP formulations and their routes of administration in the relevant jurisdiction.
- 13 August 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
Pharmacokinetic/Pharmacodynamic Analysis of Quinidine‐Induced Dominant Frequency Reduction in Thoroughbred Horses With Atrial Fibrillation
Quinidine has long been used for the pharmacological treatment of atrial fibrillation (AF) in horses; however, the plasma concentration required for conversion to sinus rhythm remains unclear. Dominant frequency (DF), derived from surface electrocardiograms, reflects atrial activation rate during AF. This study aimed to quantify the relationship between plasma quinidine concentration and DF using a pharmacokinetic/pharmacodynamic (PK/PD) approach. Ten Thoroughbred horses with naturally occurring AF received quinidine sulfate via a nasogastric tube. Plasma quinidine concentrations and DF values, calculated from digitized atrial fibrillatory segments, were measured during treatment. PK/PD was analyzed using a sigmoid inhibitory E max model, with typical parameters including a baseline DF of 6.27 Hz, a maximal DF reduction of 3.63 Hz, a theoretical minimum DF of 2.64 Hz, an EC 50 of 0.78 μg/mL, and a Hill coefficient of 1.81. Nine horses converted to sinus rhythm, with median DF decreasing from 6.4 Hz to 3.0 Hz immediately before conversion. Model simulations indicated a pharmacodynamic plateau, with an increase in plasma quinidine concentration from 4 to 5 μg/mL resulting in only a 0.06‐Hz reduction in DF. A model‐predicted plasma quinidine concentration of 2.6 μg/mL achieved a DF of 3.0 Hz and may represent a target concentration for conversion.
- 13 August 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
Pharmacokinetic/Pharmacodynamic Analysis of Quinidine‐Induced Dominant Frequency Reduction in Thoroughbred Horses With Atrial Fibrillation
Quinidine has long been used for the pharmacological treatment of atrial fibrillation (AF) in horses; however, the plasma concentration required for conversion to sinus rhythm remains unclear. Dominant frequency (DF), derived from surface electrocardiograms, reflects atrial activation rate during AF. This study aimed to quantify the relationship between plasma quinidine concentration and DF using a pharmacokinetic/pharmacodynamic (PK/PD) approach. Ten Thoroughbred horses with naturally occurring AF received quinidine sulfate via a nasogastric tube. Plasma quinidine concentrations and DF values, calculated from digitized atrial fibrillatory segments, were measured during treatment. PK/PD was analyzed using a sigmoid inhibitory E max model, with typical parameters including a baseline DF of 6.27 Hz, a maximal DF reduction of 3.63 Hz, a theoretical minimum DF of 2.64 Hz, an EC 50 of 0.78 μg/mL, and a Hill coefficient of 1.81. Nine horses converted to sinus rhythm, with median DF decreasing from 6.4 Hz to 3.0 Hz immediately before conversion. Model simulations indicated a pharmacodynamic plateau, with an increase in plasma quinidine concentration from 4 to 5 μg/mL resulting in only a 0.06‐Hz reduction in DF. A model‐predicted plasma quinidine concentration of 2.6 μg/mL achieved a DF of 3.0 Hz and may represent a target concentration for conversion.
- Open Access
- 1 May 2026
- Published by Elsevier in SSRN Electronic Journal
Biofilm-forming Ability and Antiseptic and Antimicrobial Susceptibility of Bacterial Strains Derived from Surgical-site Infections in Equine Orthopedic Surgery
Surgical site infection (SSI) is a serious complication of equine orthopedic surgery. Biofilm formation by the causative bacteria contributes to treatment failure by conferring tolerance to antimicrobial agents and disinfectants; however, data on biofilm formation and antiseptic or antimicrobial exposure in equine clinical isolates are limited.Our objectives were to evaluate the biofilm-forming ability of bacterial strains isolated from postoperative equine orthopedic SSI and to assess the susceptibility of established biofilms to disinfectants and antimicrobial agents after short-term exposure.A total of 102 bacterial strains were evaluated. Biofilms were formed using a 96-well plate with a peg-lid system, and biofilm biomass was quantified spectrophotometrically. Biofilms were exposed for 10 min to five agents at concentrations suitable for mucosal application in equine practice: povidone–iodine, chlorhexidine, benzalkonium chloride, gentamicin, and ampicillin. Viable bacteria were quantified by colony-forming unit counts, and effects were expressed as log reductions relative to controls.Biofilm-forming ability varied among bacterial groups, with Acinetobacter spp. showing the highest optical density (1.68 ± 0.91) and methicillin-sensitive Staphylococcus aureus exhibiting lower values (0.12 ± 0.08). Povidone–iodine showed high bactericidal activity across all bacterial groups (>5 log10 CFU reduction). In Gram-negative bacteria, it achieved significantly greater reductions than chlorhexidine and benzalkonium chloride (1–3 log10 CFU reduction). Antimicrobial agents showed no measurable bactericidal activity against established biofilms.Biofilm formation at surgical sites should be considered following equine orthopedic surgery. In this in vitro study, povidone–iodine had greater activity than other agents against established biofilms, suggesting its potential usefulness for biofilm-associated surgical site disinfection.
- 1 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBiofilm-forming Ability and Antiseptic and Antimicrobial Susceptibility of Bacterial Strains Derived from Surgical-site Infections in Equine Orthopedic Surgery
Surgical site infection (SSI) is a serious complication of equine orthopedic surgery. Biofilm formation by the causative bacteria contributes to treatment failure by conferring tolerance to antimicrobial agents and disinfectants; however, data on biofilm formation and antiseptic or antimicrobial exposure in equine clinical isolates are limited.Our objectives were to evaluate the biofilm-forming ability of bacterial strains isolated from postoperative equine orthopedic SSI and to assess the susceptibility of established biofilms to disinfectants and antimicrobial agents after short-term exposure.A total of 102 bacterial strains were evaluated. Biofilms were formed using a 96-well plate with a peg-lid system, and biofilm biomass was quantified spectrophotometrically. Biofilms were exposed for 10 min to five agents at concentrations suitable for mucosal application in equine practice: povidone–iodine, chlorhexidine, benzalkonium chloride, gentamicin, and ampicillin. Viable bacteria were quantified by colony-forming unit counts, and effects were expressed as log reductions relative to controls.Biofilm-forming ability varied among bacterial groups, with Acinetobacter spp. showing the highest optical density (1.68 ± 0.91) and methicillin-sensitive Staphylococcus aureus exhibiting lower values (0.12 ± 0.08). Povidone–iodine showed high bactericidal activity across all bacterial groups (>5 log10 CFU reduction). In Gram-negative bacteria, it achieved significantly greater reductions than chlorhexidine and benzalkonium chloride (1–3 log10 CFU reduction). Antimicrobial agents showed no measurable bactericidal activity against established biofilms.Biofilm formation at surgical sites should be considered following equine orthopedic surgery. In this in vitro study, povidone–iodine had greater activity than other agents against established biofilms, suggesting its potential usefulness for biofilm-associated surgical site disinfection.
- Open Access
- 21 April 2026
- Published by Elsevier in SSRN Electronic Journal
Effects of constant rate infusion of a fixed-dose combination of medetomidine and vatinoxan on cardiopulmonary function and gastrointestinal motility in standing Thoroughbred horses
Background: A fixed-dose medetomidine (MED) and vatinoxan (VTX) combination has recently become commercially available. Unlike atipamezole (ATIP), VTX is a peripherally selective α2-adrenoceptor antagonist. MED–VTX administered as a constant rate infusion (CRI) may offer safer sedation for horses by reducing MED-associated peripheral adverse effects.Aims/objectives: To evaluate the sedative, cardiopulmonary, and gastrointestinal effects of MED–VTX or MED–ATIP, administered as a CRI, compared with MED alone in Thoroughbred horses.Methods: In this blinded three-way crossover study, six healthy Thoroughbreds received an intravenous (IV) bolus of MED (7 μg/kg), followed by 60-min CRI at 5 μg/kg/h. Group M (gM) received MED alone, Group MV (gMV) received MED + VTX (140 μg/kg IV, CRI at 100 μg/kg/h), and Group MA (gMA) received MED + ATIP (140 μg/kg IV, CRI at 100 μg/kg/h). Sedation was assessed using descriptive scales, including head height, stimulus response score and ataxia score. Heart rate (HR), respiratory rate (RR), arrhythmias, and defecation were recorded.Results: Compared with the gM, sedation scales were maintained in the gMV but were significantly reduced in the gMA. The HR and RR did not differ significantly among groups. Second-degree atrioventricular block was observed in one, five, and six horses in the gMV, gM, and gMA, respectively. Defecation occurred in all horses in the gMV (median: 2.5 times, range: 1–4 times) but none in the other groups.Conclusion: Continuous MED–VTX administration provides effective sedation while reducing proarrhythmic risk and gastrointestinal inhibitory effects in Thoroughbred horses.
- 21 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEffects of constant rate infusion of a fixed-dose combination of medetomidine and vatinoxan on cardiopulmonary function and gastrointestinal motility in standing Thoroughbred horses
Background: A fixed-dose medetomidine (MED) and vatinoxan (VTX) combination has recently become commercially available. Unlike atipamezole (ATIP), VTX is a peripherally selective α2-adrenoceptor antagonist. MED–VTX administered as a constant rate infusion (CRI) may offer safer sedation for horses by reducing MED-associated peripheral adverse effects.Aims/objectives: To evaluate the sedative, cardiopulmonary, and gastrointestinal effects of MED–VTX or MED–ATIP, administered as a CRI, compared with MED alone in Thoroughbred horses.Methods: In this blinded three-way crossover study, six healthy Thoroughbreds received an intravenous (IV) bolus of MED (7 μg/kg), followed by 60-min CRI at 5 μg/kg/h. Group M (gM) received MED alone, Group MV (gMV) received MED + VTX (140 μg/kg IV, CRI at 100 μg/kg/h), and Group MA (gMA) received MED + ATIP (140 μg/kg IV, CRI at 100 μg/kg/h). Sedation was assessed using descriptive scales, including head height, stimulus response score and ataxia score. Heart rate (HR), respiratory rate (RR), arrhythmias, and defecation were recorded.Results: Compared with the gM, sedation scales were maintained in the gMV but were significantly reduced in the gMA. The HR and RR did not differ significantly among groups. Second-degree atrioventricular block was observed in one, five, and six horses in the gMV, gM, and gMA, respectively. Defecation occurred in all horses in the gMV (median: 2.5 times, range: 1–4 times) but none in the other groups.Conclusion: Continuous MED–VTX administration provides effective sedation while reducing proarrhythmic risk and gastrointestinal inhibitory effects in Thoroughbred horses.
- 5 March 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (4) , 385-391
Plasma and Urinary Elimination Profiles of Medetomidine Metabolites in Horses for the Purpose of Doping and Medication Control
Medetomidine, an α₂‐adrenergic agonist, is widely used as a sedative in horses. While its pharmacological effects are established, limited data exist on elimination of its metabolites, 3′‐hydroxy medetomidine (HMD) and 3′‐carboxy medetomidine (CMD), which are of regulatory interest. HMD is currently targeted in plasma and urine under International Screening Limits (ISLs) established by the International Federation of Horseracing Authorities (IFHA). In this study, seven Thoroughbreds received 6.3 μg/kg of medetomidine intravenously. Blood and urine were collected for 96 h and analyzed by LC–MS/MS after solid‐phase extraction with and without enzymatic hydrolysis. Parent drug was detectable in plasma up to 4 h but absent in urine. HMD was quantifiable in plasma to 48 h and urine to 72 h, while CMD, with a distinct profile, was measurable in plasma to 32 h and urine to 72 h. Based on the ISLs, the detection times (DTs) for both plasma and urine were 48 h. Pharmacokinetic modeling estimated clearance at 2.15 L/h/kg and steady‐state distribution volume at 1.90 L/kg. These findings show rapid clearance of medetomidine and extended metabolite excretion. The DT of HMD aligns with loss of pharmacological effect, supporting current ISLs and reinforcing the rationale for targeting HMD, with CMD providing supplementary regulatory insight.
- 5 March 2026
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (4) , 385-391
Plasma and Urinary Elimination Profiles of Medetomidine Metabolites in Horses for the Purpose of Doping and Medication Control
Medetomidine, an α₂‐adrenergic agonist, is widely used as a sedative in horses. While its pharmacological effects are established, limited data exist on elimination of its metabolites, 3′‐hydroxy medetomidine (HMD) and 3′‐carboxy medetomidine (CMD), which are of regulatory interest. HMD is currently targeted in plasma and urine under International Screening Limits (ISLs) established by the International Federation of Horseracing Authorities (IFHA). In this study, seven Thoroughbreds received 6.3 μg/kg of medetomidine intravenously. Blood and urine were collected for 96 h and analyzed by LC–MS/MS after solid‐phase extraction with and without enzymatic hydrolysis. Parent drug was detectable in plasma up to 4 h but absent in urine. HMD was quantifiable in plasma to 48 h and urine to 72 h, while CMD, with a distinct profile, was measurable in plasma to 32 h and urine to 72 h. Based on the ISLs, the detection times (DTs) for both plasma and urine were 48 h. Pharmacokinetic modeling estimated clearance at 2.15 L/h/kg and steady‐state distribution volume at 1.90 L/kg. These findings show rapid clearance of medetomidine and extended metabolite excretion. The DT of HMD aligns with loss of pharmacological effect, supporting current ISLs and reinforcing the rationale for targeting HMD, with CMD providing supplementary regulatory insight.
- Open Access
- 25 October 2025
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (1) , 32-50
A Meta‐Analysis of International Flunixin Pharmacokinetics in Horses: Toward Regulatory Harmonization and Individualized Detection Times Using Bayesian Paradigm
Flunixin meglumine is widely used to manage pain and inflammation in horses, and its regulation requires robust pharmacokinetic analysis for harmonization. In this study, we conducted a meta‐analysis of flunixin disposition using plasma and urine concentration data from 65 horses across four countries to robustly estimate pharmacokinetic parameters in setting screening limits (SLs) for controlling medications in horses. A population (POP) model was developed using nonlinear mixed‐effects model analysis. The irrelevant plasma concentration (IPC) and irrelevant urine concentration (IUC) were determined to be 1.9 and 70.2 ng/mL, respectively, with a typical urine‐to‐plasma ratio (Rss) of 35.9. Using the current International Federation of Horseracing Authorities (IFHA) screening limits (ISLs) (1 ng/mL for plasma; 100 ng/mL for urine), a longer detection time (DT) was observed for plasma than for urine, especially after multiple doses, as plasma ISL corresponds to a slower terminal elimination phase. Increasing the current plasma ISL from 1 to 3 ng/mL—while keeping the current urine ISL at 100 ng/mL—could better align the plasma and urine DTs. As a limitation of this study, both Standardbred and Thoroughbred data were included, and further data collection is needed to fully ascertain potential breed‐specific effects. Moreover, this POP model also enabled relatively accurate Bayesian estimation of individual withdrawal times (WTs) from limited data. Clinicians could apply this Bayesian approach to making informed WT recommendations for horses when sufficient data is available. While existing non‐POP statistical models remain viable, they may require a more conservative approach to WT estimation than Bayesian methods.
- 25 October 2025
- Published by Wiley in Drug Testing and Analysis
- Vol. 18 (1) , 32-50
Open AccessA Meta‐Analysis of International Flunixin Pharmacokinetics in Horses: Toward Regulatory Harmonization and Individualized Detection Times Using Bayesian Paradigm
Flunixin meglumine is widely used to manage pain and inflammation in horses, and its regulation requires robust pharmacokinetic analysis for harmonization. In this study, we conducted a meta‐analysis of flunixin disposition using plasma and urine concentration data from 65 horses across four countries to robustly estimate pharmacokinetic parameters in setting screening limits (SLs) for controlling medications in horses. A population (POP) model was developed using nonlinear mixed‐effects model analysis. The irrelevant plasma concentration (IPC) and irrelevant urine concentration (IUC) were determined to be 1.9 and 70.2 ng/mL, respectively, with a typical urine‐to‐plasma ratio (Rss) of 35.9. Using the current International Federation of Horseracing Authorities (IFHA) screening limits (ISLs) (1 ng/mL for plasma; 100 ng/mL for urine), a longer detection time (DT) was observed for plasma than for urine, especially after multiple doses, as plasma ISL corresponds to a slower terminal elimination phase. Increasing the current plasma ISL from 1 to 3 ng/mL—while keeping the current urine ISL at 100 ng/mL—could better align the plasma and urine DTs. As a limitation of this study, both Standardbred and Thoroughbred data were included, and further data collection is needed to fully ascertain potential breed‐specific effects. Moreover, this POP model also enabled relatively accurate Bayesian estimation of individual withdrawal times (WTs) from limited data. Clinicians could apply this Bayesian approach to making informed WT recommendations for horses when sufficient data is available. While existing non‐POP statistical models remain viable, they may require a more conservative approach to WT estimation than Bayesian methods.
- 9 October 2025
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (1) , 1-6
Plasma and Urine Pharmacokinetics of Intravenous Pridinol in Thoroughbreds for Its Medication Control
We examined the pharmacokinetics of intravenous pridinol in six thoroughbred horses. Each horse received a single 20 mg dose of pridinol mesylate via the jugular vein, and plasma and urine samples were collected over 72 h. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) was used to quantify pridinol concentrations in plasma and urine, allowing for the calculation of pharmacokinetic parameters. A three‐compartment model best fit the plasma elimination data. Using the Toutain model, irrelevant plasma and urine concentrations were estimated to be 0.00284 and 0.000612 ng/mL, respectively. Key pharmacokinetic parameters were clearance rate, 1.27 L/h/kg; steady‐state volume of distribution, 2.07 L/kg; and steady‐state urine‐to‐plasma ratio, 0.211. These findings can help establish regulatory thresholds for pridinol in horse racing and equestrian sports.
- 9 October 2025
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (1) , 1-6
Plasma and Urine Pharmacokinetics of Intravenous Pridinol in Thoroughbreds for Its Medication Control
We examined the pharmacokinetics of intravenous pridinol in six thoroughbred horses. Each horse received a single 20 mg dose of pridinol mesylate via the jugular vein, and plasma and urine samples were collected over 72 h. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) was used to quantify pridinol concentrations in plasma and urine, allowing for the calculation of pharmacokinetic parameters. A three‐compartment model best fit the plasma elimination data. Using the Toutain model, irrelevant plasma and urine concentrations were estimated to be 0.00284 and 0.000612 ng/mL, respectively. Key pharmacokinetic parameters were clearance rate, 1.27 L/h/kg; steady‐state volume of distribution, 2.07 L/kg; and steady‐state urine‐to‐plasma ratio, 0.211. These findings can help establish regulatory thresholds for pridinol in horse racing and equestrian sports.
- 7 October 2025
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (1) , 94-98
Pharmacokinetics of Remimazolam Versus Midazolam After Intravenous Administration to Horses
Remimazolam (RMZ) is a new short‐half‐life benzodiazepine used in humans. We compared the pharmacokinetics and sedative effects of RMZ with those of midazolam (MDZ) in Thoroughbred horses. Six Thoroughbreds received a single IV dose of RMZ 0.05 mg/kg or MDZ 0.05 mg/kg in a randomized crossover design. Blood samples were collected, and plasma RMZ and MDZ concentrations were measured by LC–MS/MS. Plasma concentrations were analyzed by using non‐compartmental analysis and a nonlinear mixed effect model. The half‐life of RMZ (0.77 ± 0.15 h) was significantly shorter than that of MDZ (3.7 ± 0.3 h). The bootstrap estimates of the parameters (mean ± SD) for RMZ and MDZ were 14.0 ± 1.1 L/kg/h and 0.45 ± 0.02 L/kg/h for clearance; 2.01 ± 0.26 L/kg and 1.31 ± 0.10 L/kg for the distribution volume of steady state. RMZ clearance was significantly higher than MDZ clearance in a comparison of post hoc values for the six horses. Wobble, observed as muscle relaxation/ataxia and a diminished stimulus response to RMZ, was observed from immediately after administration until 5 min later; the response generally disappeared after 10 min. Clinical trials will determine the place of RMZ in total intravenous anesthesia for rapid and smooth recovery in horses.
- 7 October 2025
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 49 (1) , 94-98
Pharmacokinetics of Remimazolam Versus Midazolam After Intravenous Administration to Horses
Remimazolam (RMZ) is a new short‐half‐life benzodiazepine used in humans. We compared the pharmacokinetics and sedative effects of RMZ with those of midazolam (MDZ) in Thoroughbred horses. Six Thoroughbreds received a single IV dose of RMZ 0.05 mg/kg or MDZ 0.05 mg/kg in a randomized crossover design. Blood samples were collected, and plasma RMZ and MDZ concentrations were measured by LC–MS/MS. Plasma concentrations were analyzed by using non‐compartmental analysis and a nonlinear mixed effect model. The half‐life of RMZ (0.77 ± 0.15 h) was significantly shorter than that of MDZ (3.7 ± 0.3 h). The bootstrap estimates of the parameters (mean ± SD) for RMZ and MDZ were 14.0 ± 1.1 L/kg/h and 0.45 ± 0.02 L/kg/h for clearance; 2.01 ± 0.26 L/kg and 1.31 ± 0.10 L/kg for the distribution volume of steady state. RMZ clearance was significantly higher than MDZ clearance in a comparison of post hoc values for the six horses. Wobble, observed as muscle relaxation/ataxia and a diminished stimulus response to RMZ, was observed from immediately after administration until 5 min later; the response generally disappeared after 10 min. Clinical trials will determine the place of RMZ in total intravenous anesthesia for rapid and smooth recovery in horses.